Author pages are created from data sourced from our academic publisher partnerships and public sources.
Assessment and management of polycystic ovary syndrome: summary of an evidence‐based guideline
Helena J Teede, Marie L Misso, Amanda A Deeks, Lisa J Moran, Bronwyn G A Stuckey, Jennifer L A Wong, Robert J Norman and Michael F Costello on behalf of the Guideline Development Groups
Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.
The new millennium has brought intense focus of interest on the risk of cardiovascular disease in women. The polycystic ovary syndrome (PCOS) is a common endocrine disorder in women characterised by… Expand
Assessment of thyroid function during pregnancy: first‐trimester (weeks 9–13) reference intervals derived from Western Australian women
- Rhonda Gilbert, N. Hadlow, +4 authors E. Lim
- The Medical journal of Australia
- 1 September 2008
Objective: To establish first‐trimester‐specific reference intervals for thyroid function tests in pregnant Australian women.
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
- B. Ascott-Evans, N. Guañabens, +5 authors M. Melton
- Archives of internal medicine
- 14 April 2003
BACKGROUND Many women using hormone replacement therapy (HRT) will discontinue HRT and lose its bone-protective effect. Methods to preserve bone density in these women need to be explored. This… Expand
Postpartum thyroid dysfunction: clinical assessment and relationship to psychiatric affective morbidity
Postpartum thyroid dysfunction (PPTD), diagnosed using biochemical criteria, is usually transient with a wide range of reported prevalence rates. The specific clinical and psychiatric morbidity… Expand
Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome.
- Andrea J. Cussons, G. Watts, V. Burke, J. Shaw, P. Zimmet, B. Stuckey
- Human reproduction
- 1 October 2008
BACKGROUND Polycystic ovary syndrome (PCOS) is associated with insulin resistance and features in common with the metabolic syndrome (MetS)--factors shown to predict cardiovascular risk and type 2… Expand
Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy
Both nonalcoholic fatty liver disease (NAFLD) and the polycystic ovary syndrome (PCOS) have a strong association with multiple cardiovascular risk factors. A number of studies have demonstrated a… Expand
Management of menopausal symptoms in patients with breast cancer: an evidence-based approach.
Increasing numbers of women have menopausal symptoms after treatment for breast cancer. These symptoms can result directly from cancer treatments (such as oophorectomy, ovarian suppression,… Expand
Genome-wide association study with 1000 genomes imputation identifies signals for nine sex hormone-related phenotypes
- K. Ruth, Purdey J. Campbell, +13 authors J. Perry
- Biology, Medicine
- European Journal of Human Genetics
- 27 May 2015
Genetic factors contribute strongly to sex hormone levels, yet knowledge of the regulatory mechanisms remains incomplete. Genome-wide association studies (GWAS) have identified only a small number of… Expand
Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary…
- J. Walsh, L. Shiels, +7 authors Andrea J. Cussons
- The Journal of clinical endocrinology and…
- 1 October 2003
T(4) is standard treatment for hypothyroidism. A recent study reported that combined T(4)/liothyronine (T(3)) treatment improved well-being and cognitive function compared with T(4) alone. We… Expand